Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
Tirzepatide
120
CHF
CHF 120.00
In stock
AG-CP3-0043-M0055 mgCHF 120.00
AG-CP3-0043-M02525 mgCHF 360.00
AG-CP3-0043-M100100 mgCHF 1'100.00
BULK available!
Research Use Only (RUO). NOT ALLOWED FOR USE IN HUMANS.
| Product Details | |
|---|---|
| Synonyms | LY3298176 |
| Product Type | Chemical |
| Properties | |
| Formula |
C225H348N48O68 |
| MW | 4813.5 |
| Sequence |
H-Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diacid-gamma-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 |
| CAS | 2023788-19-2 |
| Source/Host Chemicals | Synthetic. |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White lyophilized powder. |
| Solubility | Soluble in water or PBS (5mg/ml). |
| InChi Key | BTSOGEDATSQOAF-SMAAHMJQSA-N |
| Smiles | N[C@H](C(NC(C)(C)C(N[C@@H](CCC(O)=O)C(NCC(N[C@]([C@H](O)C)([H])C(N[C@H](C(N[C@]([C@H](O)C)([H])C(N[C@@H](CO)C(N[C@H](C(N[C@H](C(N[C@@H](CO)C(N[C@]([C@@H](C)CC)([H])C(NC(C)(C)C(N[C@@H](CC(C)C)C(N[C@H](C(N[C@@H](CCCCN)C(N[C@]([C@@H](C)CC)([H])C(N[C@H](C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)C(N[C@H](C(N[C@H](C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@]([C@@H](C)CC)([H])C(N[C@H](C(NCC(NCC(N1CCC[C@H]1C(N[C@@H](CO)C(N[C@@H](CO)C(NCC(N[C@H](C(N2CCC[C@H]2C(N3CCC[C@H]3C(N4CCC[C@H]4C(N[C@@H](CO)C(N)=O)=O)=O)=O)=O)C)=O)=O)=O)=O)=O)=O)=O)C)=O)=O)=O)CC5=CNC6=C5C=CC=C6)=O)=O)=O)CC7=CC=CC=C7)=O)C)=O)=O)=O)C)=O)=O)=O)CC(O)=O)=O)=O)=O)=O)=O)CC(C=C8)=CC=C8O)=O)CC(O)=O)=O)=O)=O)CC9=CC=CC=C9)=O)=O)=O)=O)=O)CC%10=CC=C(O)C=C%10 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Keep cool and dry. |
| Use/Stability | Stable for at least 1 year after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.
-
Tirzepatide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner. Tirzepatide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.
-
Tirzepatide comprises a 39 amino acid linear synthetic peptide conjugated to a C20 fatty diacid moiety through a hydrophilic linker at the lysine residue at position 20. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. It contains two non-coded amino acid residues (Aib, α-amino isobutyric acid) at positions 2 and 13).
Product References
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept: T. Coskun, et al.; Mol. Metab. 18, 3 (2018)
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial: J.P. Frias, et al.; Lancet 392, 2180 (2018)
- Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors: E. Yuliantie, et al.; Biochem. Pharmacol. 177, 114001 (2020)
- The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists: S. Urva, et al.; Diabetes Obes. Metab. 22, 1886 (2020)
- Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes: J.P. Frias; Expert Rev. Endocrinol. Metab. 15, 379 (2020) (Review)
- Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes: M.K. Thomas, et al.; J. Clin. Endocrinol. Metab. 106, 388 (2021)
- Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review: V.P. Chavda, et al.; Molecules 27, 4315 (2022) (Review)
Related Products
